Phanes Completes Phase 2 Enrollment for Spevatamig in PDAC
SAN DIEGO, California, June 22, 2026 Phanes Therapeutics has announced the successful completion of patient enrollment in its Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN DIEGO, California, June 22, 2026 Phanes Therapeutics has announced the successful completion of patient enrollment in its Phase...
LUND, Sweden, June 22, 2026 Hamlet BioPharma AB has announced a significant expansion of its U.S. clinical development program...
